ASCO 2020: Scientific advances & what’s impacting doctors and patientsDespite going virtual due to the COVID-19 pandemic, Jennifer Harris, an immuno-oncology expert from Syneos Health told pharmaphorum’s Share XASCO 2020: Scientific advances & what’s impacting doctors and patientshttps://deep-dive.pharmaphorum.com/magazine/future-of-oncology-2020/asco-2020-scientific-advances-and-the-impact-on-doctors-and-patients/
BMS launches digital Advocacy Exchange for patient groups affected by COVID-19Bristol Myers-Squibb and digital health firm GRYT Health have teamed up to develop an ‘Advocacy Exchange’ virtual platform Share XBMS launches digital Advocacy Exchange for patient groups affected by COVID-19https://pharmaphorum.com/views-analysis-digital/bms-launches-digital-advocacy-exchange-for-patient-groups-affected-by-covid-19/
After Celgene deal, BMS shoots up pharma market cap rankingsBristol-Myers Squibb $74 billion takeover of Celgene saw it shoot up the list of top 20 pharma companies Share XAfter Celgene deal, BMS shoots up pharma market cap rankingshttps://pharmaphorum.com/news/after-celgene-deal-bms-shoots-up-pharma-market-cap-rankings/
ASCO 2020 round-up: Virtual conference still delivers the dramaASCO may have been virtual this year because of the COVID-19 pandemic, but there were still some show-stopping Share XASCO 2020 round-up: Virtual conference still delivers the dramahttps://pharmaphorum.com/views-analysis-oncology/asco-2020-round-up-virtual-conference-still-delivers-the-drama/
Mereo raises $70m as TIGIT cancer drug progresses in clinicMereo BioPharma has raised $70m to develop its next-generation anti-TIGIT cancer checkpoint inhibitor drug. The finance round was led by OrbiMed and Share XMereo raises $70m as TIGIT cancer drug progresses in clinichttps://pharmaphorum.com/news/mereo-raises-70m-as-tigit-cancer-drug-progresses-in-clinic/
BMS launches COVID-19 delayed MS drug Zeposia in USBristol-Myers Squibb opted not to launch its new multiple sclerosis therapy Zeposia when it got FDA approval in Share XBMS launches COVID-19 delayed MS drug Zeposia in UShttps://pharmaphorum.com/news/bms-launches-covid-19-delayed-ms-drug-zeposia-in-us/
Competition heats up in BCMA CAR-T as J&J, BMS update myeloma trialsBristol-Myers Squibb’s anti-BCMA CAR-T therapy ide-cel is in pole position to reach the market, but could face tough Share XCompetition heats up in BCMA CAR-T as J&J, BMS update myeloma trialshttps://pharmaphorum.com/news/bcma-jnj-bms-myeloma-trials/
Roche’s Tecentriq gains new first-line lung cancer useRoche has an inroad into the lucrative first-line lung cancer market after its immunotherapy Tecentriq gained FDA approval in a subset of patients. Tecentriq (atezolizumab) Share XRoche’s Tecentriq gains new first-line lung cancer usehttps://pharmaphorum.com/news/roches-tecentriq-gains-new-first-line-lung-cancer-use/
Celgene investors’ CVR payment looks rocky, as FDA rejects ide-cel fileThe chances of former shareholders in Celgene missing out on the big pay-out from their contingent value right Share XCelgene investors’ CVR payment looks rocky, as FDA rejects ide-cel filehttps://pharmaphorum.com/news/celgene-investors-merger-payment-looks-rocky-as-fda-rejects-ide-cel-file/
